Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating

Core Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is recognized as one of the 14 best US stocks for long-term investment [1] - BMO Capital has raised its price target for Regeneron from $725 to $850, maintaining an Outperform rating, citing a recovery in stock price and expected strong performance from Dupixent [2] - In Q3 2025, Regeneron's Eylea net sales in the US rose by 10% to $431 million, while combined sales with the original version decreased by 28% year-over-year to $1.11 billion, with overall revenue showing a modest growth of 1% to $3.75 billion [3] - Regeneron is collaborating with Tessera Therapeutics to develop TSRA-196, a gene therapy for alpha-1 antitrypsin deficiency, with plans for regulatory approvals by year-end [4] Financial Performance - Eylea's net sales in the US increased by 10% to $431 million in Q3 2025 [3] - Combined sales of Eylea with the original version fell by 28% year-over-year to $1.11 billion [3] - Overall revenue for Regeneron in Q3 2025 was $3.75 billion, reflecting a modest growth of 1% compared to the previous year [3] Collaborations and Innovations - Regeneron is working with Tessera Therapeutics on TSRA-196, targeting the treatment of alpha-1 antitrypsin deficiency [4] - The collaboration aims to address the underlying gene mutation associated with the condition [4] - Tessera plans to seek regulatory approvals from clinical trials by the end of the year [4]